C21 Investments (CXXI) AI Stock Analysis

• Market Cap: C$82.86M
• Dividend Yield: N/A
• Average Volume (3M): 41.58K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.38
• Revenue Growth: 23.29%
• EPS Growth: 33.65%
• Country: CA
• Employees: 114
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 118,040,070
• 10 Day Avg. Volume: 50,757
• 30 Day Avg. Volume: 41,578
• PEG Ratio: 1.66
• Price to Book (P/B): 1.70
• Price to Sales (P/S): 1.37
• P/FCF Ratio: 34.86
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: C$0.44 ▼(-0.23% Downside)
• Action: Reiterated Date: 03/20/26
• Date: Action: Reiterated 03/20/26

The score is driven primarily by improving operating performance and strong TTM revenue growth, supported by manageable leverage. It is held back by continued net losses and uneven cash-flow durability, while technical indicators are mostly neutral and valuation is limited by a negative P/E and no dividend support.

Positive Factors

Vertical integration & multi-channel sales

Owning cultivation, processing and retail channels creates durable margin capture and supply control. Vertical integration reduces reliance on third-party suppliers, supports product consistency and branding, and gives flexibility to shift volumes between retail and wholesale across regulatory cycles.

Strong revenue rebound and improving operating margins

A sustained revenue rebound and materially improved EBIT margin indicate improving unit economics and demand recovery. If trends hold, improved operating profitability provides a pathway to absorb fixed costs, fund reinvestment, and convert top-line gains into durable cash generation over the medium term.

Manageable and improving leverage

Lower and improving debt-to-equity boosts financial flexibility and reduces interest burden risk. A more conservative leverage profile supports capital allocation for store expansion or operating investments, and improves resilience to regulatory or demand shocks relative to highly levered peers.

Negative Factors

Ongoing net losses

Persistent net losses and negative ROE constrain internal capital formation and limit strategic optionality. Until sustained net profitability is achieved, the company may remain dependent on external financing for growth, making long-term planning and dividend prospects uncertain.

Declining FCF durability

A meaningful decline in free cash flow reduces the firm's ability to self-fund store openings, cultivation improvements, or working capital. Uneven cash conversion raises funding sensitivity and increases the probability that management will need to raise external capital during adverse market conditions.

Historic earnings volatility and inconsistency

Repeated swings between profit and loss indicate fragile earnings quality and operational inconsistency. This volatility complicates forecasting, undermines stakeholder confidence, and makes it harder to demonstrate sustained improvements to partners, regulators, and lenders over the medium term.

C21 Investments Business Overview & Revenue Model

Company Description

C21 Investments (CXXI) is a diversified investment company focused on the cannabis sector, particularly in the cultivation, processing, and retail of cannabis products. The company operates in various states where cannabis is legal, providing a wide range of products that include dried flower, edibles, and concentrates. C21 Investments aims to leverage its expertise in the cannabis industry to capitalize on growth opportunities and enhance shareholder value.

How the Company Makes Money

C21 Investments makes money primarily by selling cannabis and cannabis-derived products through two main channels: (1) retail sales at company-owned dispensaries, where revenue is generated from direct-to-consumer transactions and the company captures retail margin on products it sells (including its own products and, where offered, third-party products); and (2) wholesale sales, where the company supplies cannabis flower and/or manufactured products into the broader regulated market and earns revenue based on volumes sold and prevailing market prices. A key driver of earnings in this model is vertical integration—when the company grows and processes cannabis that it then sells through its own retail stores, it can capture value across cultivation/processing and retail. Additional factors that can influence revenue and profitability include product mix (e.g., flower vs. manufactured products), store traffic and same-store sales performance, cultivation yields and production efficiency, wholesale pricing dynamics, and compliance with state-level cannabis regulations. Significant partnerships: null.

C21 Investments Financial Statement Overview

Summary

Revenue rebounded sharply (+70.5% TTM) and operating profitability improved (EBIT margin ~8.5% vs ~4.0% prior), with manageable leverage (debt-to-equity ~0.41). Offsetting this, the company remains unprofitable (TTM net margin ~-9.0%, ROE ~-10.4%) and cash-flow durability is uneven with meaningfully lower free cash flow versus the prior annual period.

Income Statement

TTM (Trailing-Twelve-Months) revenue rebounded sharply (+70.5%), and operating profitability improved versus the prior annual period (EBIT margin ~8.5% vs ~4.0%). However, the company remains unprofitable at the bottom line (TTM net margin ~-9.0%), following multiple periods of losses and volatility versus earlier profitable years (2022–2023). Overall: strong top-line momentum and improving operating performance, but earnings quality and consistency are still weak.

Balance Sheet

Leverage looks manageable with debt-to-equity around 0.41 in TTM (Trailing-Twelve-Months), improved from the most recent annual period (~0.46) and far better than the highly levered 2021 profile. That said, profitability on shareholder capital is negative in TTM (return on equity ~-10.4%), reflecting ongoing net losses, which limits balance-sheet strength despite a solid equity base.

Cash Flow

TTM (Trailing-Twelve-Months) cash generation is positive with operating cash flow (~$1.4M) and free cash flow (~$1.3M) both above zero, and free cash flow broadly tracks reported losses (free cash flow to net income ~0.91). The key concern is durability: free cash flow declined meaningfully versus the prior annual period (large negative growth) and operating cash flow covers only a modest portion of reported earnings power, pointing to uneven cash conversion and potential funding sensitivity if profitability does not improve.

Breakdown	Dec 2025	Mar 2025	Apr 2023	Apr 2022	Apr 2020
Income Statement
Total Revenue	33.27M	30.12M	28.29M	28.89M	33.47M
Gross Profit	13.99M	12.56M	11.15M	13.40M	18.05M
EBITDA	4.57M	2.90M	2.63M	6.98M	5.79M
Net Income	-3.44M	-3.97M	-3.31M	293.21K	-7.83M
Balance Sheet
Total Assets	54.89M	57.00M	54.53M	58.31M	68.81M
Cash, Cash Equivalents and Short-Term Investments	2.42M	2.63M	2.41M	1.89M	6.24M
Total Debt	10.95M	13.15M	10.72M	12.14M	27.30M
Total Liabilities	28.05M	28.32M	23.48M	24.00M	43.47M
Stockholders Equity	26.84M	28.68M	31.05M	34.32M	25.34M
Cash Flow
Free Cash Flow	1.31M	-2.63M	5.46M	5.46M	9.70M
Operating Cash Flow	1.44M	1.19M	5.90M	5.90M	9.92M
Investing Cash Flow	223.14K	-3.12M	-390.93K	-390.93K	-1.10M
Financing Cash Flow	-1.78M	1.27M	-6.68M	-6.68M	-5.70M

C21 Investments Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.44
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CXXI, the sentiment is Negative. The current price of 0.44 is above the 20-day moving average (MA) of 0.40, above the 50-day MA of 0.43, and above the 200-day MA of 0.42, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 45.65 is Neutral, neither overbought nor oversold. The STOCH value of 43.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:CXXI.

C21 Investments Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XLY	67 Neutral	C$177.72M	2.37	32.74%	―	27.38%	―
CXXI	54 Neutral	C$82.86M	-18.63	-12.42%	―	23.29%	33.65%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CWEB	51 Neutral	C$157.83M	-1.15	-119.94%	―	-4.23%	37.33%
JUSH	47 Neutral	C$121.95M	-2.14	88.51%	―	3.17%	-24.07%
LEEF	46 Neutral	C$67.07M	-3.62	163.84%	―	―	―
PLTH	42 Neutral	C$65.07M	-0.45	-90.71%	―	2.19%	-91.41%